November 19th 2021
JAMA Internal Medicine editor and a UCSF colleague wrote in a New England Journ of Medicine opinion piece that the decision highlights the need to establish a new requirement that would make coverage decisions contingent on evidence of benefit for Medicare population.
FDA Update: Keytruda and Aduhelm News Leads the Week
July 10th 2021Keytruda loses one indication but gains another, Biogen narrows use of Aduhelm, Padcev gets regular approval and expanded indication, Amgen submits application for asthma biologic, agency issues complete response letter for diabetes prevention therapy teplizumab, Novartis resubmits NDA for inclisiran.
Read More
Treating Sleep Apnea With CPAP Therapy Lowers the Risk of Heart Problems, COVID-19
June 30th 2021Data presented at the virtual Sleep 2021 meeting by the Annual American Academy of Sleep Medicine suggests treating sleep apnea or obstructive sleep apnea is important for heart health and better prevents chances of COVID-19.
Read More
SGLT2 Inhibitor Use Stunted for Black, Female, Lower Income Type 2 Diabetes Patients
April 21st 2021Access to care and other health disparities result in the low use of novel therapies for Black, female and lower income type 2 diabetes patients. If these barriers aren't addressed, disparities among kidney and cardiovascular patients may worsen in the U.S.
Read More
How to Reduce Your Long-Term Risk from Cardiovascular Disease, Poor Metabolic Health
February 22nd 2021February is American Heart Month and the perfect time to think about our cardiovascular health. Cardiovascular diseases are those that affect the heart and blood vessels and include stroke, coronary artery disease (CAD), heart failure, and other poor heart and vascular health outcomes.
Read More
Prime Therapeutics research a thumbs up for Entresto — with caveats
November 18th 2020Entresto (sacubitril-valsartan) didn’t get a lot of love from payers after it was approved in 2015 because of its expense and the crowded armamentarium for heart failure. But Entresto has since made its way into guidelines for reduced ejection fraction heart failure, sometimes called systolic heart failure.
Read More
AHA Scientific Sessions 2020: Study Shows Polypill With Aspirin Slightly Better Than Polypill Alone
November 13th 2020Overall, the Polycap polypill (simvastatin, atenolol, hydrochlorothiazide, ramipril) falls well short of the high expectations for the polypill approach to cardiovascular disease risk reduction.
Read More